Применение триметазидина в кардиологии: современные клинико-фармакологические аспекты

1. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
2. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580–8.
3. Mody FV, Singh BN, Mohiuddin IH et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischaemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82: 42k–49k.
4. Sentex E, Sergiel JP, Lucien A, Grinberg A. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem 1997; 175: 153–62.
5. Pornin M, Harpey C, Allal J et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. Clin Trials Metaanal 1994; 29: 49–56.
6. Koylan N, Bilge AK, Adalet K et al. Comparison of the effects of trimetazidine and diltiazem on exercise performance in patients with coronary heart disease. The Turkish trimetazidine study (TTS). Acta Cardiol 2004; 59 (6): 644–50.
7. Detry JM, Sellier P, Pennaforte S et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37 (3): 279–88.
8. Szwed H, Sadowski Z, Elikowski W et al. Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22 (24): 2267–74.
9. Chazov EI, Lepakchin VK, Zharova EA et al. Trimetazidine in angina combination therapy — the TACT study: Trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. Am J Ther 2005; 12 (1): 35–42.
10. Danchin N, Marzilli M, Parkhomenko A, Ribeiro JP. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology 2011; 120 (2): 59–72.
11. Kim JS, Kim CH, Jeong MH. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean acute myocardial infarction registry. Clin Res Cardiol 2013; 102 (12): 915–22.
12. Fragasso G, Palloshi A, Puccetti P et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48 (5): 992–8.
13. Zhou X, Chen J. Is treatment with trimetazidine beneficial in patients with chronic heart failure? PLoS One 2014; 9 (5).
14. Гайсин И.Р., Газимзянова А.С. и др. Триметазидин эффективен в реабилитации больных после протезирования клапанов сердца: результаты рандомизированного контролируемого годичного исследования.. Фарматека. 2014; 6: 6–11.
15. Задионченко В.С., Шехян Г.Г., Ялымов А.А и др. Микроциркуляция и морфофункциональный статус больных хронической сердечной недостаточностью при лечении триметазидином. Кардиоваскулярная терапия и профилактика. 2004; 3 (5): 74–80.
16. Шапошник И.И., Введенская Н.В. Анализ эффективности триметазидина пролонгированного действия в лечении ишемической болезни сердца, развившейся на фоне нормального артериального давления. Фарматека. 2012; 17.

Г.С.Аникин

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России;
ФГБУ Поликлиника №3 Управления делами Президента РФ